Biovie Inc (BIVI) Return on Investment ROI from the fourth quarter of 2026 to fourth quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Biovie Inc's ROI from its fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Biovie Inc's ROI in the fourth quarter of 2026?
Biovie Inc recorded a cumulative net loss of $-22 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on investment (ROI) of -124.4%.
Within the Healthcare sector 646 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2026 from 3321 to 4035.
BioVie Inc. a clinical-stage company engaged in the development of transformative therapies for neurological disorders, has recently announced the full funding of its upcoming clinical trial, designated PD-202. This study aims to evaluate the efficacy of Bezisterim in early-stage Parkinson s disease patients. Despite facing substantial financial challenges, as evidenced by a cumulative net loss of $32 million over the preceding twelve months and a significant decline in return on investment (ROI), the company s latest developments suggest a commitment to advancing therapeutic options for patients grappling with this debilitating condition. Parkinson s disease, a progressive neurodegenerative disorder, presents significant challenges not only to affected individuals but also to the healthcare system at large. With management strategies often limited to symptomatic relief, the need for innovative therapeutic solutions has never been more pressing. BioVie Inc. through its pioneering approach, aims to address this gap with the initiation of the PD-202 trial. Development of Bezisterim The PD-202 trial is characterised as a double-blind, randomized, placebo-controlled study, a design that recognises the inherent uncertainties associated with clinical efficacy assessments. Bezisterim, the focal agent in this investigation, has shown promise in preclinical studies. This upcoming trial marks a vital step in evaluating its potential role in moderating the progression of Parkinson s disease in its early stages.
In the ever-evolving landscape of healthcare, emerging companies like BioVie Inc. find themselves on a precarious tightrope, balancing innovative aspirations against stark financial realities. Recently, BioVie (Nasdaq: BIVI), a clinical-stage biopharmaceutical firm specializing in therapies for chronic debilitating conditions—including liver disease and neurological disorders—announced significant financial maneuvers aimed at bolstering its future, yet the challenges it faces underline the complexities burgeoning biotech companies must navigate. Recent Developments and Financial OverviewOn October 22, 2024, BioVie disclosed the successful closing of a registered direct offering of 4,443,000 shares, priced at $1.50 per share. This offering aligns with Nasdaq s at-the-market regulations, allowing the company to raise much-needed capital amidst pressing financial challenges. However, this move comes against a backdrop of notable struggles, as the company reported a cumulative net loss of $32 million over the past year, resulting in a staggering negative return on investment (ROI) of -244.86%. Amidst a competitive healthcare sector, BioVie ranked 3448 in ROI, a slight improvement from its position of 3656 in the previous quarter, but still reflective of its ongoing financial woes.
BioVie, a biopharmaceutical company known for its innovative approaches to treating neurodegenerative conditions, has recently announced promising clinical data suggesting that its lead compound, Bezisterim (NE3107), has an epigenetic basis for modulating inflammation and biological aging. These findings, presented at the 11th Aging Research and Drug Discovery Meeting, alongside the upcoming SUNRISE-PD Phase 2 trial focusing on early Parkinson s Disease, mark crucial advancements in understanding Bezisterim s therapeutic potential. This article outlines the essential discoveries surrounding Bezisterim and explores their implications for BioVie and the field of pharmaceutical sciences.The quest for novel therapeutics in the realm of neurodegenerative diseases has gained renewed vigor with recent advances in epigenetic research. BioVie has positioned itself at the forefront of this exploration, with its candidate drug, Bezisterim, demonstrating significant promise in modulating inflammatory processes and contributing to biological health over the aging spectrum.
The Formation of Advisory Board and Financial Struggles: Assessing the Impact on BioVie Inc s Long COVID Trial BioVie Inc, a prominent pharmaceutical company, has recently announced the formation of an Advisory Board to guide and accelerate their groundbreaking Bezisterim long COVID Phase 2b trial. This trial has garnered significant support from the U.S. Department of Defense, highlighting the critical nature of BioVie s research in addressing the long-term effects of COVID-19. Simultaneously, the company s financial performance has faced challenges, as recorded in a press release statement. BioVie Inc has reported a cumulative net loss of $-37 million during the twelve months ending in the third quarter of 2023. This dire financial situation has further led to a negative return on investment (ROI) of -260.42%, painting a concerning picture for stakeholders.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
